Shares of Fulcrum Therapeutics plummeted 52% on Tuesday following the company’s decision to completely halt the development of pociredir, its lead oral drug candidate for sickle-cell disease. The sudden cancellation came after the U.S. Food and Drug Administration (FDA) signaled sweeping safety concerns regarding the drug’s mechanism, pushing Fulcrum to aggressively cut costs and open the door to a potential sale or merger.
The Catalyst: Systemic Risks and the PRC2 Complex
Pociredir was engineered to treat sickle-cell disease—an inherited and debilitating blood disorder—by increasing fetal hemoglobin levels. It targeted a specific sub-unit of the PRC2 protein complex, which naturally suppresses that hemoglobin production.
However, the regulatory environment for this mechanism soured dramatically after Ipsen’s cancer drug, Tazverik—which targets the same PRC2 complex—was pulled from global markets due to a heightened risk of secondary blood cancers. While Fulcrum submitted data arguing that pociredir targeted a different component of the complex and held a distinct safety profile, the FDA flatly rejected the distinction, ruling that any therapeutic acting on the PRC2 complex carries systemic malignancy risks.
Industry Fallout and Pivot to Survival
The development caught Wall Street by surprise, especially given pociredir’s previously strong efficacy data. A wave of downgrades immediately followed:
-
Brokerage Reaction: At least three major brokerages drastically cut their price targets and downgraded the stock.
-
Corporate Pivot: Faced with a barren lead pipeline, Fulcrum announced immediate cost-cutting measures to preserve its remaining cash reserves. The leadership team is now actively exploring strategic alternatives, including a total corporate sale or merger.
This collapse marks yet another high-profile casualty in the sickle-cell therapeutic space, following Pfizer’s total withdrawal of its approved drug Oxbryta over distinct safety concerns.
